HOME >> BIOLOGY >> NEWS
Researchers Discover Why Some Athletes' Performances Fail To Improve On A Live-High, Train-Low Regimen

DALLAS - December 30, 1998 - Exercise physiology researchers at UT Southwestern Medical Center at Dallas have learned why certain athletes don't respond to the internationally accepted "live-high, train-low" paradigm. The regimen - essentially living in the thin mountain air while training at lower altitudes to increase athletic endurance - is not effective in athletes unable to produce a sustained amount of a crucial red blood cell-increasing hormone.

"We've figured out some of the differences between the athletes who do and don't respond to altitude training. So now we hope to extend this research and predict who will and who won't respond with a screening test," said Dr. Benjamin Levine, associate professor of internal medicine at UT Southwestern and director of the Institute for Exercise and Environmental Medicine (IEEM) - a collaboration between UT Southwestern and Presbyterian Hospital of Dallas.

Exercise physiologists have known for years that, in most cases, the body responds to high altitude by producing more red blood cells to boost oxygen levels. That formed the basis of Levine's original 1997 study performed in collaboration with Dr. James Stray-Gundersen, a former assistant professor of surgery at UT Southwestern who now works with Norway's Olympic ski team.

The new study was published in the October issue of Journal of Applied Physiology. Levine's team, including Stray-Gundersen and UT Southwestern postdoctoral fellow Dr. Robert Chapman, looked at data from previous altitude studies, specifically, erythropoietin (EPO) concentrations in 39 collegiate runners living at high altitudes. Those who responded to the live-high, train-low regimen showed a significantly larger increase in EPO concentration than the nonresponders. The researchers theorized that this increased EPO concentration allows the body to make more red cells while at high altitudes and that, in turn, increases maximal oxygen uptake, which was shown through higher scores in
'"/>

Contact: Jennifer Haigh-Manley
jhaigh@mednet.swmed.edu
214-648-3404
UT Southwestern Medical Center
30-Dec-1998


Page: 1 2 3

Related biology news :

1. Researchers determine genetic cause of Timothy syndrome
2. Researchers find color sensitive atomic switch in bacteria
3. Researchers identify protein promoting vascular tumor growth
4. Researchers devise potent new tools to curb ivory poaching
5. Researchers create nanotubes that change colors, form nanocarpet and kill bacteria
6. Researchers ID chlorophyll-regulating gene
7. Researchers develop fast track way to discover how cells are regulated
8. Researchers identify distinctive signature for metastatic prostate cancer
9. Researchers report new gene test for isolated cleft lip and palate
10. Researchers discover why mutant gene causes colon cancer
11. Researchers identify the genomes controlling elements

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/7/2019)... ... May 07, 2019 , ... ... Long Beach Convention and Entertainment Center from May 15- 17. At booth #226, ... solutions. These include flexible software, biometric hardware, mobile apps, specialized industry solutions, advanced ...
(Date:5/2/2019)... ... April 30, 2019 , ... Global ... announces today that Holotype HLA and other Omixon products will be featured in ... Immunogenetics (EFI) in Lisbon, Portugal. Among the major scientific events, Omixon’s ...
(Date:5/2/2019)... (PRWEB) , ... May 01, 2019 , ... ... Board of Directors has appointed John Rakow, the Company’s General Counsel, as Interim ... Richman and Zac Apte, are currently on administrative leave. There will also be ...
Breaking Biology News(10 mins):
(Date:4/9/2019)... ... ... The American Society of Gene & Cell Therapy (ASGCT) is excited to ... the presidential line of succession, at the 22nd Annual Meeting . Members of ... three-year term (2019-2021). , All five incoming members of the ASGCT Board of ...
(Date:4/8/2019)... , ... April 08, 2019 , ... US Capital ... a $15 million preferred equity investment in the privately held pharmaceutical company, S1 Biopharma ... drug, Lorexys, is targeted at female hypoactive sexual dysfunction disorder and is ready to ...
(Date:4/4/2019)... ... April 02, 2019 , ... Biomeme, Inc. , a ... latest field-ready solution for performing PCR, RT-PCR, qPCR, and Isothermal tests called ... Rosland Franklin, an English chemist and X-ray crystallographer who made significant contributions to ...
(Date:3/29/2019)... ... March 28, 2019 , ... Specific Diagnostics announced today ... with a second stage of funding for Specific’s Reveal™ rapid antibiotic susceptibility test ... of the $1.7 million already awarded by CARB-X. The additional $1.7M will enable ...
Breaking Biology Technology:
Cached News: